TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
St. Jude Medical Furthers the Company’s Legacy of Heart Valve ...
WEBMay 16, 2016 · ST. PAUL, Minn., St. Jude Medical, Inc., a global medical device company, today announced the U.S. launch of the company’s most advanced tissue valve — the Trifecta™ valve with Glide™ Technology (GT) — for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves.Designed with feedback from a cohort of international physicians, the Trifecta GT ...
Complications After TAVR: Manageable, But Important to Consider
WEBNov 10, 2011 · Vascular complications after TAVR, including hematomas, dissections and perforations, are frequent and have been associated with increased mortality. Vessel-sheath size ratio, calcification and center experience appear to be important predictors. Meticulous CTA screening, site/operator experience, reduced …
RAPID: Positive Top-line Results for Etripamil Nasal Spray in ...
WEBOct 17, 2022 · A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular tachycardia (PSVT), according to top-line results of the RAPID trial released Monday.. Drugmaker Milestone Pharmaceuticals said the phase III trial met its primary endpoint, demonstrating a higher rate of conversion to normal sinus rhythm within 30 ...
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese …
WEBJun 9, 2022 · At 72 weeks, the mean reduction in body weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group. In pounds lost, those changes translated to 35.5, 48.9, 52.0, and 5.3, respectively. Overall, more than 90% of those on tirzepatide 15 mg achieved the co-primary endpoint of weight ...
News | tctmd.com
WEBCellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction. Positive changes in prognostic biomarkers including infarct size, left ventricular dimensions and NT-proBNP level support the anti-remodeling effect of ProtheraCytes cell therapy in post-myocardial infarction patients at risk of ...
None of the Usual Suspects? Troponin Elevation Still Warrants …
WEBJan 11, 2019 · The Higher the Troponin, the Higher the Risk. To TCTMD, Eggers noted the advent of hs-cTn tests in North America has ushered in fears that ubiquitous positive troponin tests would lead to too many patients being labelled as “at risk” despite a clear diagnosis, prompting a cascade of tests. Other data from …
Nitrates and Erectile Dysfunction Meds? Increasingly Common, …
WEBApr 20, 2022 · By L.A. McKeown. Despite widely publicized warnings about the potential interaction between nitrates prescribed for angina and oral (phosphodiesterase type 5) PDE5 inhibitors taken for erectile dysfunction, a Danish study suggests that prescriptions for the latter have steadily increased over the last 20 years in men who take nitrates, but ...
Skip to content